Triple

T11074695
Position Surface form Disambiguated ID Type / Status
Subject Docetaxel E261833 entity
Predicate tradeName P1500 FINISHED
Object Taxotere
Taxotere is a chemotherapy medication containing docetaxel, commonly used to treat various cancers such as breast, lung, prostate, and gastric cancers.
 E902896 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Taxotere | Statement: [Docetaxel, tradeName, Taxotere]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Taxotere
Context triple: [Docetaxel, tradeName, Taxotere]
  • A. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • B. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • C. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • D. Seagen
    Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
  • E. Zaltrap
    Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Taxotere
Triple: [Docetaxel, tradeName, Taxotere]
Generated description
Taxotere is a chemotherapy medication containing docetaxel, commonly used to treat various cancers such as breast, lung, prostate, and gastric cancers.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Taxotere
Target entity description: Taxotere is a chemotherapy medication containing docetaxel, commonly used to treat various cancers such as breast, lung, prostate, and gastric cancers.
  • A. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • B. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • C. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • D. Seagen
    Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
  • E. Zaltrap
    Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994efb608190a81bc8c4d16ddbd0 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3c8cc77988190aad54f56dbd0f8cf completed April 18, 2026, 6:09 p.m.
NEDg Description generation batch_69e3cefc00148190a1850dc6e31523c3 completed April 18, 2026, 6:35 p.m.
NED2 Entity disambiguation (via description) batch_69e3d014a644819092c76aa02b573ca9 completed April 18, 2026, 6:40 p.m.
Created at: April 8, 2026, 9:26 p.m.